Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Sentry enzyme blocks two paths to Parkinson's disease

Sentry enzyme blocks two paths to Parkinson's disease

February 02, 2007

St. Jude study shows the enzyme GST pi stands at the crossroads of several pathways that lead to the death of dopaminergic neurons and prevents both cell degeneration and cell suicide

The degeneration of brain cells that occurs in Parkinson's disease may be caused by either externally provoked cell death or internally initiated suicide when the molecule that normally prevents these fatal alternatives is missing, according to studies in mouse models by investigators at St. Jude Children's Research Hospital.




Parkinson's disease is a disease in which nerve cells in part of the brain called the substantia nigra die, resulting in the loss of dopamine, a nerve-signaling molecule that helps control muscle movement. The absence of dopamine from these cells, called dopaminergic neurons, causes a loss of muscle control, trembling and lack of coordination.

The molecule that prevents damage to the substantia nigra is an enzyme called GST pi ("pie"). This molecule stands like a sentry at the crossroads of several biochemical pathways, any one of which can lead to Parkinson's disease, the researchers reported in an article in the Feb. 1 early online edition of Proceedings of the National Academy of Sciences.

The job of the antioxidant GST pi is to protect the cell from death caused by either environmental toxins (externally evoked cell death), such as herbicides and pesticides, or a self-destruction process called apoptosis (cell suicide), triggered by certain stressful conditions in the cell. If GST pi levels are reduced or this enzyme is overwhelmed by toxins, these nerves are at increased risk of death. Previous research has shown that the ability of GST pi to protect cells against toxic molecules is directly linked to the ability of cancer cells with excessive amounts of this enzyme to reduce the effectiveness of chemotherapy.

The finding that GST pi plays a key role in preventing Parkinson's disease suggests that measuring levels of this enzyme might be an effective way to determine individuals at risk for developing this disease, according to Richard Smeyne, Ph.D., an associate member of the Department of Developmental Neurobiology at St. Jude. "In the future, treatments that increase GST pi levels in the substantia nigra might help to prevent or delay the onset of Parkinson's disease or reduce its severity," said Smeyne, the report's senior author.

GST pi is one of a family of similar enzymes that eliminate free radicals generated by pesticides and other chemicals. Two members of this family are present in the brain, but only one of them, GST pi, is found in the dopaminergic neurons of the substantia nigra. Free radicals are highly unstable molecules that readily interact with other molecules, causing cell damage.

The study sheds light on the cause of most cases of Parkinson's disease, which currently are unexplained. "The majority of these cases of Parkinson's disease appear to arise because individuals who have a genetic susceptibility to the disease are exposed to environmental toxins such as pesticides and herbicides, which trigger the formation of free radicals that kill dopaminergic neurons in the substantia nigra," Smeyne said. "We also know that GST pi blocks the process of cell suicide triggered by stresses that the cell can't overcome, such as an increase in the presence of free radicals or a loss of the cell's ability to produce energy.".

Smeyne's team showed that of the two known types of GST in the brain, only GST pi was present in the dopaminergic neurons that are lost in Parkinson's disease. The scientists then treated two different populations of mice with MPTP, a chemical that causes loss of these cells, in order to determine if levels of GST pi changed. In mice known to be sensitive to MPTP, there was a complete but transient loss of GST pi in the dopaminergic neurons of the substantia nigra, while the same area of the brain in MPTP-resistant mice never completely lost GST pi and recovered their original levels within 12 hours.

In addition, the team showed that when MPTP-resistant mice were treated with this drug, the presence of GST pi in the dopaminergic neurons prevented activation of cJUN, a molecule that triggers apoptosis. These findings are evidence that GST pi prevents apoptosis in dopaminergic neurons of the substantia nigra, Smeyne said.

The investigators also showed in cell culture studies that blocking production of GST pi in substantia nigra cells left them vulnerable to MPTP, causing a significant death rate among these cells. In addition, when the investigators blocked GST pi production in the dopaminergic neurons of the substantia nigra, about one-quarter of them died, even though they were not treated with MPTP. "This suggests that even in the absence of MPTP the enzyme GST pi plays a critical role in preventing cell death that may occur with the natural buildup of free radicals," Smeyne said.

Finally, the investigators studied the effect of MPTP on the substantia nigra of normal, "wild-type" mice and mice that lacked one (+/-) or both (-/-) genes for GST pi. Wild-type and GST pi (+/-) mice showed similar resistance to MPTP, but GST pi (-/-) mice lost slightly less than half of their dopaminergic neurons following treatment with MPTP. Six hours after MPTP treatment, the formation of free radicals increased 300 percent in the substantia nigra of GST pi (-/-) mice compared with the substantia nigra of GST pi (+/+) mice. These results are additional evidence that GST pi may play an important role in preventing Parkinson's disease," Smeyne said.

Results of the St. Jude study showing the importance of GST pi could help to explain previous work by other researchers linking loss of this enzyme to destruction of dopaminergic neurons. For example, there is some evidence that alterations in the gene for GSP pi are linked to increased risk of Parkinson's disease after pesticide exposure. Also, although most Parkinson's disease cases have no known cause, experts believe that they are caused by the interaction of genetic susceptibility to Parkinson's disease with exposure to a variety of environmental factors, such as pesticides and herbicides.

"Therefore, the new findings bring researchers a step closer to understanding why Parkinson's disease occurs and potentially how to develop more effective treatments for it,\\\

St. Jude Children's Research Hospital




More Parkinson’s Disease Current Events and Parkinson’s Disease News Articles
  Parkinson s Disease II : Aging and Neuroendocrine Relationships (Advances in experimental medicine and biology)
by C. E. Finch (Editor)



Lappare Foti Root Shampoo with Lavender & Menthol (8oz)

Lappare Foti Root Shampoo with Lavender & Menthol (8oz)
by EMPIRE VITAMINS INC

FO-TI has been used by Chinese over the years. Many people are taking FO-TI and they have observed that their hair is getting darker. It also helps for faster growth of the hair besides making it less gray.The hair is composed of proteins. The melanin in the hair is in charge for the color of the hair. The amount of melanin that is present is responsible for the various colors of the hair. The darker the hair color, the more the melanin content. As people age, the quantity of the melanin in the hair reduces. This causes the hair to become gray and at some point becomes color white. Having a balance diet and sufficient nutrients can help slow down the graying effect on the hair. FO-TI is a herbal plant that can be useful in preventing the graying of the hair when used in shampoos.

Natrol Extra Strength ENADA NADH, 5 mg, MicroTablets - 30 ea

Natrol Extra Strength ENADA NADH, 5 mg, MicroTablets - 30 ea
by Natrol

The Energizing CoEnzyme.
A Patented Formula. The Only Stable NADH. Maximum Bioavailability. Dietary Supplement.

Natrol® Enada®'s NADH is a patented dietary ingredient designed for those whose active lifestyles demand the very best.  As a coenzyme, NADH plays a key role in the energy production of our cells and neurotransmitter processes.*  Natrol offers Enada's NADH - the only stable form of NADH in the marketplace today.  This exclusive patented supplement assures maximum bioavailability. 

*The FDA has not evaluated this statement. This product is not intended to diagnose, treat, cure or prevent disease.  If you have or suspect a medical condition, consult your healthcare professional prior to use. 

NADH (Vegetable source) (reduced 5 nicotinamide...

  Parkinsons Disease and Movement Disorders (Two Colour)
by Mehotra (Author)

The revised volume has included almost all the common disorders found in clinical practice. The volume will be of great importance to more physicians practising nephrology in South East Asia.

Parkinson’s Disease Chart

Parkinson’s Disease Chart
by American 3B Scientific

Parkinson’s Disease Chart Parkinson’s Disease ChartThis thickly laminated anatomical chart is printed on premium glossy (200 g) UV resistant paper and comes with 2 sided lamination (125 micron, 5.0 Mil) and metal eyelets to make the chart easy to display. It comes in a convenient poster size 50 x 67 cm (20x26’’) and can be written on and wiped off with non permenant markers. The 125 micron lamination ensures the chart does not curl up at the edges and the UV treament ensures the chart does not get a faded yellow color over time.Measurements:50 x 67 cm Weight: 0,15 kgProduct photo may not exactly match the product offered for sale. Please refer to the product description.

  Coping with Parkinson' s Disease
by Am. Parkinson Disease Asso., St. Louis (Publisher)



Speed and Amplitude of Movement in Patients with  Parkinson?s disease: Pilot study to classify and measure movement  impairment

Speed and Amplitude of Movement in Patients with Parkinson?s disease: Pilot study to classify and measure movement impairment
by Alberto Espay (Author)

Slowness of movement (?bradykinesia?) is the most important deficit in Parkinson?s disease (PD). Current clinical rating of bradykinesia in PD does not separate the dimensions of slowness and amplitude reduction. We categorized patterns of movement in PD patients on a biaxial classification of speed and amplitude using an electromagnetic tracking device (Polhemus) seeking to determine whether these categories may differentially contribute to motor impairment and disability. Motor impairment was worst in patients with very impaired amplitude and best in patients with normal amplitude. Categories of speed impairment did not show a similar relationship. The Schwab & England disability scale decreased with higher severity levels of the amplitude category but not...

  The Medical Clinics of North America: Parkinson' S Disease and Parkinsonian Syndromes
by Matthew B. Stern And Howard I. Hurtig (Author)



  Gale Encyclopedia of Nursing and Allied Health: Parkinson's disease
by Jr., MD, DrPH L. Fleming Fallon (Author)

The article is excerpted from Gale Encyclopedia of Nursing and Allied Health.
This 5-vol. set provides more than 850 entries covering topics in nursing and allied health written for students and professionals in the field. Alphabetically arranged entries cover topics in body systems and functions, conditions and common diseases, issues and theories, techniques and practices, and devices and equipment. The Encyclopedia covers all major health professions, including nursing, physical therapy, occupational therapy, respiratory therapy, medical lab technology, emergency medical technology, dental assistance, pharmacology and nutrition. In addition, the set features approximately 400 photographs and illustrations; appendices of related organizations, agencies and associations;...

Ask the Doctor About Parkinson's Disease

Ask the Doctor About Parkinson's Disease
by Michael S. Okun (Author), Hubert H. Fernandez (Author)

Parkinson’s disease is a chronic and progressive disease which can cause life-changing symptoms, including tremors, balance problems, and rigidity of limbs. Derived from Ask the Doctor, a website column written by the authors for the National Parkinson Foundation, this book explores frequently asked questions about the disease. It offers detailed answers to the most common questions, including the role of heredity in Parkinson’s, its symptoms and diagnosis, the effectiveness of drugs and other treatments, whether the disease’s progression can be slowed, the future of stem cell treatment in the fight against Parkinson’s disease, and many others. Written in plain, easy-to-understand language, it arms readers — whether already living with Parkinson’s disease, newly diagnosed, or...

© 2010 BrightSurf.com